Slideshows Images Quizzes

Lupron Depot 7.5

Last reviewed on RxList: 5/30/2017
Lupron Depot 7.5 Side Effects Center

Last reviewed on RxList 2/19/2016

Lupron Depot 7.5 (leuprolide acetate for depot suspension) is a man-made form of gonadotropin-releasing hormone (GnRH) that is used in men to treat the symptoms of prostate cancer. Lupron Depot 7.5 is used in women to treat symptoms of endometriosis (overgrowth of uterine lining outside of the uterus) or uterine fibroids, and is also used to treat precocious (early-onset) puberty in both male and female children. Common side effects of Lupron Depot 7.5 include hot flashes (flushing), increased sweating, night sweats, chills, clammy skin, tiredness, weakness, swelling of the ankles/feet, increased urination at night, dizziness, injection site reactions (burning, pain, redness, stinging, or bruising), acne, increased growth of facial hair, breakthrough bleeding in a female child during the first 2 months of Lupron Depot 7.5 treatment, nausea, diarrhea, constipation, stomach pain, skin redness/itching/scaling, joint or muscle pain, vaginal itching or discharge, breast swelling or tenderness, testicle pain, impotence, loss of interest in sex, depression, sleep problems (insomnia), or memory problems.

The recommended dose of Lupron Depot is 7.5 mg for 1-month administration. It is administered under physician supervision. Other drugs may interact with Lupron Depot. Tell your doctor all medications and supplements you use. Lupron Depot must not be used during pregnancy. It may harm a fetus. If you become pregnant or think you may be pregnant, inform your doctor. Consult your doctor to discuss birth control. Non-hormonal birth control methods are recommended. It is unknown if this drug passes into breast milk. Because the effects on a nursing infant are unknown, breastfeeding is not recommended.

Our Lupron Depot 7.5 (leuprolide acetate for depot suspension) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Lupron Depot 7.5 Consumer Information

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.

Call your doctor at once if you have a serious side effect such as:

  • bone pain, loss of movement in any part of your body;
  • swelling, rapid weight gain;
  • pain, burning, stinging, bruising, or redness where the medication was injected;
  • feeling like you might pass out;
  • sudden chest pain or discomfort, wheezing, dry cough or hack;
  • painful or difficult urination;
  • urinating more often than usual;
  • high blood sugar (increased thirst, increased urination, hunger, dry mouth, fruity breath odor, drowsiness, dry skin, blurred vision, weight loss);
  • sudden numbness or weakness (especially on one side of the body), problems with speech or balance;
  • sudden headache with vision problems, vomiting, confusion, slow heart rate, weak pulse, fainting, or slow breathing; or
  • chest pain spreading to the arm or shoulder, nausea, sweating, general ill feeling.

Rare but serious side effects may include:

  • pain or unusual sensations in your back;
  • numbness, weakness, or tingly feeling in your legs or feet;
  • muscle weakness or loss of use;
  • loss of bowel or bladder control; or
  • nausea, upper stomach pain, itching, loss of appetite, dark urine, clay-colored stools, jaundice (yellowing of the skin or eyes).

Less serious side effects may include:

  • acne, increased growth of facial hair;
  • breakthrough bleeding in a female child during the first 2 months of leuprolide treatment;
  • dizziness, weakness, tired feeling;
  • hot flashes, night sweats, chills, clammy skin;
  • nausea, diarrhea, constipation, stomach pain;
  • skin redness, itching, or scaling;
  • joint or muscle pain;
  • vaginal itching or discharge;
  • breast swelling or tenderness;
  • testicle pain;
  • impotence, loss of interest in sex;
  • depression, sleep problems (insomnia), memory problems; or
  • redness, burning, stinging, or pain where the shot was given.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Read the entire detailed patient monograph for Lupron Depot 7.5 (Leuprolide Acetate for Depot Suspension)

Lupron Depot 7.5 Professional Information


Clinical Trials

In the majority of patients testosterone levels increased above baseline during the first week, declining thereafter to baseline levels or below by the end of the second week of treatment.

Potential exacerbations of signs and symptoms during the first few weeks of treatment is a concern in patients with vertebral metastases and/or urinary obstruction or hematuria which, if aggravated, may lead to neurological problems such as temporary weakness and/or paresthesia of the lower limbs or worsening of urinary symptoms (see WARNINGS section).

In a clinical trial of LUPRON DEPOT 7.5 mg for 1-month administration, the following adverse reactions were reported in 5% or more of the patients during the initial 24-week treatment period regardless of causality.

LUPRON DEPOT 7.5 mg for 1-Month Administration (N=56)

  N (%)
Body as a Whole
  General pain 13 (23.2)
  Infection 3 (5.4)
Cardiovascular System
  Hot flashes/sweats* 32 (57.1)
Digestive System
  GI disorders 8 (14.3)
Metabolic and Nutritional Disorders
  Edema 8 (14.3)
Nervous System
  Libido decreased* 3 (5.4)
Respiratory System
  Respiratory disorder 6 (10.7)
Urogenital System
  Urinary disorder 7 (12.5)
  Impotence* 3 (5.4)
  Testicular atrophy* 3 (5.4)
* Due to the expected physiologic effect of decreased testosterone levels.

In this same study, the following adverse reactions were reported in less than 5% of the patients on LUPRON DEPOT 7.5 mg for 1-month administration.

Body as a Whole -Asthenia, Cellulitis, Fever, Headache, Injection site reaction, Neoplasm;

Cardiovascular System -Angina, Congestive heart failure;

Digestive System -Anorexia, Dysphagia, Eructation, Peptic ulcer;

Hemic and Lymphatic System -Ecchymosis;

Musculoskeletal System -Myalgia;

Nervous System -Agitation, Insomnia/sleep disorders, Neuromuscular disorders;

Respiratory System -Emphysema, Hemoptysis, Lung edema, Sputum increased;

Skin and Appendages -Hair disorder, Skin reaction;

Urogenital System -Balanitis, Breast enlargement, Urinary tract infection.

Laboratory: Abnormalities of certain parameters were observed, but their relationship to drug treatment are difficult to assess in this population. The following were recorded in ≥ 5% of patients at final visit: Decreased albumin, decreased hemoglobin/hematocrit, decreased prostatic acid phosphatase, decreased total protein, decreased urine specific gravity, hyperglycemia, hyperuricemia, increased BUN, increased creatinine, increased liver function tests (AST, LDH), increased phosphorus, increased platelets, increased prostatic acid phosphatase, increased total cholesterol, increased urine specific gravity, leukopenia.


The following adverse reactions have been identified during postapproval use of LUPRON DEPOT. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

During postmarketing surveillance, which includes other dosage forms and other patient populations, the following adverse events were reported.

Like other drugs in this class, mood swings, including depression, have been reported. There have been very rare reports of suicidal ideation and attempt. Many, but not all, of these patients had a history of depression or other psychiatric illness. Patients should be counseled on the possibility of development or worsening of depression during treatment with LUPRON.

Symptoms consistent with an anaphylactoid or asthmatic process have been rarely (incidence rate of about 0.002%) reported. Rash, urticaria, and photosensitivity reactions have also been reported.

Changes in Bone Density: Decreased bone density has been reported in the medical literature in men who have had orchiectomy or who have been treated with an LH-RH agonist analog. In a clinical trial, 25 men with prostate cancer, 12 of whom had been treated previously with leuprolide acetate for at least six months, underwent bone density studies as a result of pain. The leuprolide-treated group had lower bone density scores than the nontreated control group. It can be anticipated that long periods of medical castration in men will have effects on bone density.

Pituitary apoplexy: During post-marketing surveillance, rare cases of pituitary apoplexy (a clinical syndrome secondary to infarction of the pituitary gland) have been reported after the administration of gonadotropin-releasing hormone agonists. In a majority of these cases, a pituitary adenoma was diagnosed, with a majority of pituitary apoplexy cases occurring within 2 weeks of the first dose, and some within the first hour. In these cases, pituitary apoplexy has presented as sudden headache, vomiting, visual changes, ophthalmoplegia, altered mental status, and sometimes cardiovascular collapse. Immediate medical attention has been required.

Localized reactions including induration and abscess have been reported at the site of injection.

Symptoms consistent with fibromyalgia (eg, joint and muscle pain, headaches, sleep disorders, gastrointestinal distress, and shortness of breath) have been reported individually and collectively.

Cardiovascular System - Hypotension, Myocardial infarction, Pulmonary embolism;

Respiratory, thoracic and mediastinal disorder - Interstitial lung disease;

Hepato-biliary disorder: Serious drug-induced liver injury

Hemic and Lymphatic System - Decreased WBC;

Central/Peripheral Nervous System - Convulsion, Peripheral neuropathy, Spinal fracture/paralysis;

Endocrine System - Diabetes;

Musculoskeletal System - Tenosynovitis-like symptoms;

Urogenital System - Prostate pain.

See other LUPRON DEPOT and LUPRON Injection package inserts for other events reported in women and pediatric populations.

Read the entire FDA prescribing information for Lupron Depot 7.5 (Leuprolide Acetate for Depot Suspension)

Related Resources for Lupron Depot 7.5

Health Solutions From Our Sponsors